Nature Communications (Aug 2022)

Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period

  • Pilar T. V. Florentino,
  • Flávia J. O. Alves,
  • Thiago Cerqueira-Silva,
  • Vinicius de Araújo Oliveira,
  • Juracy B. S. Júnior,
  • Adelson G. Jantsch,
  • Gerson O. Penna,
  • Viviane Boaventura,
  • Guilherme L. Werneck,
  • Laura C. Rodrigues,
  • Neil Pearce,
  • Manoel Barral-Netto,
  • Mauricio L. Barreto,
  • Enny S. Paixão

DOI
https://doi.org/10.1038/s41467-022-32524-5
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 5

Abstract

Read online

There is limited evidence of the effectiveness of the CoronaVac vaccine for children against the Omicron SARS-CoV-2 variant. Here, the authors use data from Brazil for children aged 6–11 years and estimate effectiveness of 40% against infection and 59% against severe disease at least two weeks after the second dose.